An observational study in Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Fundación Santa Fe de Bogota. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Fundación Santa Fe de Bogota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
PCSK9 inhibitors, including evolocumab and alirocumab, are lipid-lowering therapies used in patients with hyperlipidemia and atherosclerotic cardiovascular disease. This retrospective observational study aims to describe changes in low-density lipoprotein cholesterol (LDL-C) levels following the use of PCSK9 inhibitors in adult patients with hyperlipidemia and/or atherosclerotic cardiovascular disease treated at Fundación Santa Fe de Bogotá between 2018 and 2024. The study will also describe patients' clinical characteristics, treatment effectiveness, safety, adherence, and barriers to treatment access. Data will be obtained from medical records, cardiology records, and telephone interviews when needed to complete missing information.
864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.
This study's planned enrollment of 100 is below the median of 335 across 102 observational studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients over 18 years of age with hyperlipidemia and/or atherosclerotic heart disease in Bogotá.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who initiated treatment with evolocumab or alirocumab between 2018 and 2024.
Patients who received at least one dose of evolocumab or alirocumab. Patients followed by the Cardiology Department at Fundación Santa Fe de Bogotá. Patients with at least one measured and/or calculated low-density lipoprotein cholesterol (LDL-C) level within the 6 months prior to initiation of evolocumab or alirocumab.
Exclusion Criteria:
Patients without at least one LDL-C measurement after initiation of PCSK9 inhibitor therapy.
Patients without at least one LDL-C measurement within the 6 months prior to initiation of evolocumab or alirocumab.
Patients with incomplete medical records from which identification or contact information cannot be obtained.
Change in low-density lipoprotein cholesterol (LDL-C) levels
Change in low-density lipoprotein cholesterol (LDL-C) levels following treatment with evolocumab or alirocumab in patients with hyperlipidemia and/or atherosclerotic cardiovascular disease (ASCVD) during the study period.
Time frame: January-2018 to July-2024
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Santa Fe de Bogota